Dr Tyson on a Real-World Study of Blue Light Cystoscopy in High-Risk NMIBC

“The implication is that this technology, among other enhanced technologies, give us an opportunity to put our very best foot forward at the time of TURBT to try to get all of the disease resected, so that patients can be set up for success as they go on to intravesical therapy.”

Mark D. Tyson, II, MD, MPH, a urologic oncologist at Mayo Clinic, discussed data from a real-world study that evaluated blue light cystoscopy for early recognition of carcinoma in situ and/or high-risk disease as well as clinical decision making in patients with high-risk non–muscle-invasive bladder cancer (NMIBC).

Blue light cystoscopy has become an established tool in the management of NMIBC, with multiple randomized studies supporting its use, Tyson began. Although its clinical value is well recognized, questions remain regarding how the technology is being utilized in routine practice and whether it can facilitate a more risk-adapted treatment approach, particularly for patients with high-risk disease, he said. Compared with clinical trial data, real-world evidence evaluating the impact of blue light cystoscopy remains relatively limited, he noted.

To address this question, Tyson and his coauthors conducted an analysis using the Optum Research Database, a large real-world dataset that included patients who underwent blue light cystoscopy and those treated with conventional white light cystoscopy. The study authors collected data from 794 patients who received blue light cystoscopy and matched it with 4764 patients who underwent white light cystoscopy using inverse probability treatment weighting, allowing for comparisons between the 2 groups, he explained.

The analysis demonstrated that blue light cystoscopy was used more frequently in patients with carcinoma in situ (CIS), Tyson said. Although the retrospective nature of the study made it difficult to determine whether the technology detected a greater number of CIS lesions or was simply preferentially used in patients already known to have CIS, either explanation was viewed as encouraging, he noted. The findings suggest that this enhanced imaging modality is being appropriately used for higher-risk patients, where its potential benefit may be greatest, he added.

Importantly, patients who underwent blue light cystoscopy were also more likely to receive intravesical therapy and more likely to proceed to radical cystectomy, Tyson said. These findings suggest that enhanced visualization may contribute to more informed treatment decisions and more aggressive management when clinically warranted, he added.

Overall, the study supports the role of blue light cystoscopy and other enhanced imaging technologies in optimizing transurethral resection of bladder tumors, Tyson explained. By improving the ability to identify and remove disease at the time of resection, these approaches may help better position patients for subsequent intravesical therapy and improve long-term outcomes, he said. The real-world findings reinforce the value of blue light cystoscopy in contemporary NMIBC management, he concluded.